Lack of cataleptogenic potentiation with non-imidazole H3 receptor antagonists reveals potential drug-drug interactions between imidazole-based H3 receptor antagonists and antipsychotic drugs

Brain Research

Volumn 1045, Issue 1-2, 2005, Pages 142-149

  Zhang, Min ^a   Ballard, Michael E ^a   Pan, Liping ^a   Roberts, Stanley ^a   Faghih, Ramin ^a   Cowart, Marlon ^a   Esbenshade, Tim A ^a   Fox, Gerard B ^a   Decker, Michael W ^a   Hancock, Art A ^a   Rueter, Lynne E ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Antipsychotics; Catalepsy; Drug metabolism; H3 receptor; Histamine; Pharmacokinetic interaction

Indexed keywords

4 [2 [2 (2 METHYLPYRROLIDINYL)ETHYL]BENZOFURAN 5 YL]BENZONITRILE; 4 FLUOROPHENYL[[2 (METHYLPYRROLIDIN 1 YL)ETHYL]BENZOFURAN 5 YL]METHANONE; 5 (4 CYANOPHENYL) 2 [2 (2 METHYL 1 IMIDAZOLIDINYL)ETHYL]BENZOFURAN; A 431404; BENZOFURAN DERIVATIVE; CIPROXIFAN; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; HALOPERIDOL; HISTAMINE H3 RECEPTOR ANTAGONIST; IMIDAZOLE; KETOCONAZOLE; NEUROLEPTIC AGENT; RISPERIDONE; THIOPERAMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATALEPSY; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG METABOLISM; DRUG POTENTIATION; EXTRAPYRAMIDAL SYMPTOM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RISK ASSESSMENT; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZOFURANS; BRAIN CHEMISTRY; CATAPLEXY; CYTOCHROME P-450 ENZYME SYSTEM; DRUG COMBINATIONS; DRUG SYNERGISM; HALOPERIDOL; HISTAMINE; HISTAMINE ANTAGONISTS; IMIDAZOLES; KETOCONAZOLE; MALE; METABOLIC CLEARANCE RATE; PIPERIDINES; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, HISTAMINE H3; RISPERIDONE; SCHIZOPHRENIA;

EID: 21144450185     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2005.03.018     Document Type: Article

References (32)

1. 3-receptors Neuroscience 15 1985 553 562
2. L. Bacciottini, P.F. Mannaioni, M. Chiappetta, M.G. Giovannini, and P. Blandina Acetylcholine release from hippocampus of freely moving rats is modulated by thioperamide and cimetidine Inflamm. Res. 48 Suppl 1 1999 S63 S64
3. 3 receptor activation in rats Br. J. Pharmacol. 119 1996 1656 1664
4. R.L. Borison The role of cognition in the risk-benefit and safety analysis of antipsychotic medication Acta Psychiatr. Scand., Suppl. 389 1996 5 11
5. 3 receptor antagonists thioperamide and ciproxifan Behav. Brain Res. 153 2004 69 76
6. S. Caccia New antipsychotic agents for schizophrenia: pharmacokinetics and metabolism update Curr. Opin. Investig. Drugs 3 2002 1073 1080
7. 3 receptor antagonist, attenuates stimulant-induced locomotor activity in the mouse Eur. J. Pharmacol. 259 1994 107 114
8. M. Cowart, R. Faghih, G. Gfesser, M. Curtis, J.K. Pratt, Y. Bennani, G.B. Fox, T.A. Esbenshade, and A.A. Hancock The medicinal chemistry of novel H(3) antagonists Inflamm. Res. 53 Suppl. 1 2004 S69 S70
9. M. Cowart, J.K. Pratt, A.O. Stewart, Y.L. Bennani, T.A. Esbenshade, and A.A. Hancock A new class of potent non-imidazole H(3) antagonists: 2-aminoethylbenzofurans Bioorg. Med. Chem. Lett. 14 2004 689 693
10. J. Fang, and J.W. Gorrod Metabolism, pharmacogenetics, and metabolic drug-drug interactions of antipsychotic drugs Cell. Mol. Neurobiol. 19 1999 491 510
11. R. Fog, A. Randrup, and H. Pakkenberg Lesions in corpus striatum and cortex of rat brains and the effect on pharmacologically induced stereotyped, aggressive and cataleptic behaviour Psychopharmacologia 18 1970 346 356
12. G.B. Fox, J.B. Pan, T.A. Esbenshade, Y.L. Bennani, L.A. Black, R. Faghih, A.A. Hancock, and M.W. Decker Effects of histamine H(3) receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup Behav. Brain Res. 131 2002 151 161
13. 3R) antagonists with cognition enhancing properties in rats Inflamm. Res. 52 Suppl. 1 2003 S31 S32
14. 3R) antagonists in several animal models Inflamm. Res. 53 2004 S49 S50
15. 3 receptor antagonist J. Pharmacol. Exp. Ther. 313 2005 176 190
16. J.W. Grimm, and R.E. See Unique activation of extracellular striato-pallidal neurotransmitters in rats following acute risperidone Brain Res. 801 1998 182 189
17. A.A. Hancock, and G.B. Fox Cognition enhancing effects of drugs that target histamine receptors M.J. Parnham J. Bruinvels Milestones in Drug Discovery: Cognitive Enhancing Drugs 2004 Birkhauser Verlag Boston 97 114
18. N. Hussain, B.A. Flumerfelt, and N. Rajakumar Muscarinic, adenosine A(2) and histamine H(3) receptor modulation of haloperidol-induced c-fos expression in the striatum and nucleus accumbens Neuroscience 112 2002 427 438
19. A.S. Kalgutkar, T.J. Taylor, K. Venkatakrishnan, and E.M. Isin Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway Drug Metab. Dispos. 31 2003 243 249
20. W.R. Klemm Evidence for a cholinergic role in haloperidol-induced catalepsy Psychopharmacology (Berlin) 85 1985 139 142
21. T. Klockgether, M. Schwarz, L. Turski, and K.H. Sontag Catalepsy after microinjection of haloperidol into the rat medial prefrontal cortex Exp. Brain Res. 70 1988 445 447
22. 3 receptor blockade by thioperamide enhances cognition in rats without inducing locomotor sensitization Psychopharmacology (Berlin) 167 2003 363 372
23. 3-receptor antagonist J. Pharmacol. Exp. Ther. 287 1998 658 666
24. G. Lucas, N. Bonhomme, P. De Deurwaerdere, M. Le Moal, and U. Spampinato 8-OH-DPAT, a 5-HT1A agonist and ritanserin, a 5-HT2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release Psychopharmacology (Berlin) 131 1997 57 63
25. S. Morisset, U.G. Sahm, E. Traiffort, J. Tardivel-Lacombe, J.M. Arrang, and J.C. Schwartz Atypical neuroleptics enhance histamine turnover in brain via 5-hydroxytryptamine2A receptor blockade J. Pharmacol. Exp. Ther. 288 1999 590 596
26. 3 receptor antagonists potentiate methamphetamine self-administration and methamphetamine-induced accumbal dopamine release Neuropsychopharmacology 29 2004 705 717
27. 3 and dopamine D2 receptor antagonism in treatment of schizophrenia Neuroscience Conference, Program No. 956.7 2003
28. 3-receptor antagonist/inverse agonist, potentiates neurochemical and behavioral effects of haloperidol in the rat J. Neurosci. 22 2002 7272 7280
29. M. Rowland, and T.N. Tozer Clinical Pharmacokinetics Concepts and Applications Third ed. 1995 Williams and Wilkins
30. 3 receptors J. Neural Transm.: Gen. Sect. 93 1993 1 10
31. S. Tucci, R. Fernandez, T. Baptista, E. Murzi, and L. Hernandez Dopamine increase in the prefrontal cortex correlates with reversal of haloperidol-induced catalepsy in rats Brain Res. Bull. 35 1994 125 133
32. 3 receptor antagonists with human adrenal cytochrome P450 enzymes Pharmacology 66 2002 128 135